Skip to main navigation
Horizon Therapeutics plc

U.S.

  • Global
    • Brazil
    • Canada
    • Germany
    • Japan
  • Investors
  • Media Hub
  • Stories
Horizon logo
search
  • Our Company
    • About Us
    • Leadership Team
    • Corporate Social Responsibility
    • Partnering
    • Grant Programs
    • Contact Us
  • Our Science
    • Research and Development
    • Pipeline
    • Science Forward
  • Our Medicines
    • Our Portfolio
    • Medical Resources
  • Our Patients
    • Our Commitment
      • Overview
      • Responsible Pricing
    • Advocacy
      • Overview
      • Resources
    • Disease Information
    • Patient Stories
    • Patient Support
    • Expanded Access
  • Careers
    • Why Horizon
    • Who We Are
    • Benefits
    • Job Opportunities
  • Investors
    • At a Glance
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Whistleblower Hotline
      • Leadership
      • Committee Composition
      • Contact Board
    • Financials & Filings
      • Financial Information
      • SEC Filings
      • GAAP to Non-GAAP Reconciliations
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Annual Reports / Proxy Statements
    • Investors FAQs
    • IR Contact Us
    • IR Email Alerts
  • Media Center
Follow Us

Event Calendar

Overview of Teprotumumab OPTIC Phase 3 Trial Topline Results and Thyroid Eye Disease (TED)

Feb 28, 2019 at 8:00 AM EST

Supporting Materials

Teprotumumab Phase 3 Data Press Release 608.8 KB
Overview of Teprotumumab OPTIC Phase 3 Trial Topline Results & Thyroid Eye Disease (TED) 5.6 MB

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Whistleblower Hotline
    • Leadership Team
    • Committee Composition
    • Contact the Board
  • Financial & Filings
    • Financial Information
    • SEC Filings
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Annual Reports / Proxy Statements
  • Investor FAQs
  • Contact Us
  • Email Alerts
  • Offer for Horizon Therapeutics plc
Investor Contacts Tina Ventura
Senior Vice President,
Chief Investor Relations Officer
Investor-relations@horizontherapeutics.com

Ruth Venning
Executive Director,
Investor Relations and ESG
Investor-relations@horizontherapeutics.com

Erin Linnihan
Executive Director,
Investor Relations 
Investor-relations@horizontherapeutics.com
U.S. Media Contact Geoff Curtis
Executive Vice President,
Corporate Affairs & Chief
Communications Officer
media@horizontherapeutics.com
+1 888 506-2562
Ireland Media Contact Ray Gordon
Gordon MRM
ray@gordonmrm.ie
+353 (87) 2417373
Shareholder Tools

Shareholder Tools

  • Email Alerts Subscription
  • RSS News Feeds
  • Snapshot
  • Print
  • Our Company
  • Our Science
  • Our Medicines
  • Our Patients
  • Careers
  • Investors
  • Follow Us
© 2023 Horizon Therapeutics plc
  • Global Privacy Policy
  • Legal Notice
  • Cookie Policy
  • Contact Us

The information regarding our medicines and the patients they treat on this site is intended only for residents of the U.S.

You are leaving horizontherapeutics.com

You are leaving horizontherapeutics.com. You will be redirected to a website operated by an independent third party. This link is provided solely for your convenience.

Continue